Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment

Inclusion Criteria (general): * Men and women (age 18 to 85 years) * Participants must be nonfertile or using a medically approved birth control method. Additional information regarding this requirement available at screening * Body mass index (BMI) ≤42 kg/m2 (inclusive) Inclusion Criteria (for renal insufficient patients): * Patients with mild, moderate, or severe kidney impairment. Please consult with participating physicians regarding the definitions of these levels of severity. * Patients with diabetes must be treated with standard anti-diabetic therapy (diet and exercise, stable dose of sulfonylurea, insulin, or metiglinides) and agree to continue for the study duration Inclusion Criteria (for healthy subjects): * No current significant medical conditions as determined by history and physical. * Serum creatinine with a calculated creatinine clearance (CrCl) of \>80 ml/min. * Matched to renal impaired patients in the study by age (±5 years), sex and weight (±10% BMI) * Vital signs guided by the following ranges: oral body temperature between 35.0-37.2 °C systolic blood pressure, 100-140 mm Hg diastolic blood pressure, 60-110 mm Hg pulse rate, 45-90 bpm Exclusion criteria: * Pregnant or lactating female. * A history of type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, acute metabolic diabetic complications (eg, ketoacidosis or hyperosmolar state (coma)) * Subjects that have been enrolled in previous vildagliptin studies or other DPP * 4 inhibitor studies within six months * History of renal transplant or immunosuppressant therapy * Acute infections which may affect blood glucose control or other medical condition that may interfere with the interpretation of efficacy and safety data during the study * Any pre-existing or history of diabetic ulcer * Any of the following within the past 6 months: myocardial infarction (MI), coronary artery bypass surgery or percutaneous coronary intervention, unstable angina or stroke * Any of the following electrocardiogram (ECG) abnormalities: Torsades de pointes, sustained and clinically relevant ventricular tachycardia or ventricular fibrillation, second degree atrioventricular (AV) block (Mobitz 1 and 2), third degree AV block, prolonged QTc (\>500 ms) * Malignancy including leukemia and lymphoma within the last 5 years. * Liver disease such as cirrhosis or positive hepatitis B and C. * Any alcohol related hepatic disease. * Patients undergoing any method of dialysis * Use of some concomitant medications * Significant laboratory abnormalities as specified in the protocol * History of active substance abuse (including alcohol) within the past 2 years. * Smokers (i.e., 10 or more cigarettes per day) * History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures Other protocol-defined inclusion/exclusion criteria may apply